Step toward prevention: app-based exercise may protect the brain in Parkinson's risk group

NCT ID NCT07324330

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether increasing physical activity through a motivational smartphone app can slow cognitive decline in people with isolated REM sleep behavior disorder (iRBD), an early sign of Parkinson's disease and related disorders. Researchers will enroll 130 participants (80 with iRBD and 50 healthy controls) and track changes in thinking skills, brain imaging, and blood markers over one year. The app encourages users to gradually increase their daily steps and activity intensity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
motivational smartphone application (Alpha-Fit app) to increase physical activity
What this could lead to
If it works, this could point toward a simple, non-drug way to preserve thinking skills in people at high risk for Parkinson's or related diseases.
What could go wrong
This is a relatively small, early-stage study (130 participants) testing a behavioral intervention, so results may not be conclusive or widely applicable. The app-based approach also depends on participants' long-term motivation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BASAL GANGLIA DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Hospital of Bonn

    RECRUITING

    Bonn, North Rhine West-Falia, 53111, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.